A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma
Cell Reports · 2025-12 · 44 (12) · 116675
DOI: 10.1016/j.celrep.2025.116675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-12. Verfasst von Yuntian Zhang und 33 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins c-myc, Drug Resistance, Neoplasm, POU Domain Factors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT 84103, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Genetics, The Ohio State University College of Arts and Sciences, Columbus, OH 43210, USA; Department of Chemical Eng…
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Genetics, The Ohio State University College of Arts and Sciences, Columbus, OH 43210, USA.
- Radboud University, Institute for Molecules and Materials, Heyendaalseweg 135, 6525 AJ Nijmegen, the Netherlands.
Förderung
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
- US Department of Defense
- Elsa U Pardee Foundation
- University of California, San Francisco
- National Institutes of Health National Cancer Institute
- University of Utah
Zitieren
APA
Zhang, Y., Urquijo, M. A., Zitnay, R. G., Marks, K., Belote, R. L., Hansen, M. M. K., Ferita, M., Neuendorf, H. M., Liu, T., Smith, E. A., Mehrabad, E. M., Hejna, M., Moustafa, T. E., Lange, D., Hu, M., Vand-Rajabpour, F., Done, A., Becker, C. A., Lieberman, M., …, & Judson-Torres, R. L. (2025). A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell Reports, 44(12), 116675. https://doi.org/10.1016/j.celrep.2025.116675
Vancouver
Zhang Y, Urquijo MA, Zitnay RG, Marks K, Belote RL, Hansen MMK, et al. A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell Reports. 2025;44(12):116675. doi:10.1016/j.celrep.2025.116675
BibTeX
@article{Zhang2025,
author = {Zhang, Yuntian and Urquijo, Marcus A and Zitnay, Rebecca G and Marks, Kayla and Belote, Rachel L and Hansen, Maike M K and Ferita, Montana and Neuendorf, Hannah M and Liu, Tong and Smith, Eric A and Mehrabad, Elnaz Mirzaei and Hejna, Miroslav and Moustafa, Tarek E and Lange, Devin and Hu, Min and Vand-Rajabpour, Fatemeh and Done, Anne and Becker, Carly A and Lieberman, Matthew and Chang, Matthew and Lohman, Brian K and Stubben, Chris J and Reeves, Melissa Q and Zhang, Xiaoyang and Weinberger, Leor S and VanBrocklin, Matthew W and Deacon, Dekker C and Grossman, Douglas and Spike, Benjamin T and Lex, Alexander and Boyle, Glen M and Kulkarni, Rajan and Zangle, Thomas A and Judson-Torres, Robert L},
title = {A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {12},
pages = {116675},
doi = {10.1016/j.celrep.2025.116675}
}
EUVIMED